¼¼°èÀÇ Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå : Á¦Ç°º°, À¯Çüº°, Áúȯº°, Åõ¿© °æ·Îº°, ¼­ºñ½ºº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2031³â)
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
»óǰÄÚµå : 1800739
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 371 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,951,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,339,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,445,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,044,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 31.0%ÀÇ CAGR·Î È®´ëµÇ¾î 2024³â 14¾ï ´Þ·¯¿¡¼­ 2031³â¿¡´Â 70¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2031³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2025-2031³â
°ËÅä ´ÜÀ§ ±Ý¾×(10¾ï ´Þ·¯)
ºÎ¹® Á¦Ç°º°, À¯Çüº°, Áúȯº°, Åõ¿© °æ·Îº°, ¼­ºñ½ºº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸¸¦ À§ÇÑ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È »ê¾÷°è¿Í ÇаèÀÇ Çù·Â ü°è¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀÌ Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª º¹ÀâÇÑ ±ÔÁ¦ Á¤Ã¥ÀÌ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÇ »ó¾÷È­¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÄ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

2024³â Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦ ºÐ¾ß¿¡¼­´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½º ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Human Microbiome Market-IMG1

½ÃÀåÀº Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÀǾàǰ, Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦, Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áø´ÜÀ¸·Î ±¸ºÐµË´Ï´Ù. Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½º, ÇÁ¸®¹ÙÀÌ¿Àƽ½º, ½Å¹ÙÀÌ¿Àƽ½º µî 3°¡Áö ÁÖ¿ä Á¦Ç°À¸·Î ºÐ¼®µË´Ï´Ù. 2024³â Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÑ ºÎ¹®Àº ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ ±¤¹üÀ§ÇÑ »ç¿ë, ¼ÒºñÀÚÀÇ ³ôÀº ÀÎÁöµµ, ½ÃÆÇ ÁßÀÎ °Ç°­ ¹× À£ºù Á¦Ç°¿¡¼­ È®°íÇÑ ÀÔÁö¸¦ ±¸ÃàÇÑ ´öºÐÀÔ´Ï´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ½º´Â ¼ÒÈ­±â °Ç°­À» Áö¿øÇÏ°í ¸é¿ª·ÂÀ» °­È­Çϸç Àå³» ¹Ì»ý¹°ÀÇ ±ÕÇüÀ» À¯ÁöÇϱâ À§ÇØ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ¸ç, ¿¹¹æ °Ç°­ °ü¸®ÀÇ ÀÏ»óÀûÀÎ ºÎºÐÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ½º´Â ĸ½¶, ºÐ¸», µå¸µÅ©Á¦, ±â´É¼º ½Äǰ µî ´Ù¾çÇÑ ÇüÅ·ΠÆÇ¸ÅµÇ°í ÀÖÀ¸¸ç, ½±°Ô ±¸ÇÒ ¼ö ÀÖ¾î ¼ÒºñÀÚµéÀÇ ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ÀÓ»ó ¿¬±¸°¡ ƯÁ¤ ÇÁ·Î¹ÙÀÌ¿Àƽ½º ±ÕÁÖÀÇ È¿´ÉÀ» ÀÔÁõÇÏ¿© ¼ÒºñÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ½Å·Úµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ½º¸¦ ÇÁ¸®¹ÙÀÌ¿Àƽ½º, ºñŸ¹Î µî ´Ù¸¥ »ý¸®È°¼º¹°Áú°ú °áÇÕÇÒ ¼ö Àֱ⠶§¹®¿¡ ´Ù¾çÇÑ °èÃþ¿¡¼­ ÇÁ·Î¹ÙÀÌ¿Àƽ½ºÀÇ ¸Å·ÂÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ÇÁ·Î¹ÙÀÌ¿Àƽ½º´Â Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦ ºÐ¾ßÀÇ ÁÖ¿ä Á¦Ç° À¯ÇüÀÌ µÇ¾ú½À´Ï´Ù.

ÀÎü ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀåÀº ¼ÒÈ­±â Áúȯ, °¨¿°¼º Áúȯ, ³»ºÐºñ ¹× ´ë»ç Áúȯ, ±âŸ ÁúȯÀ¸·Î ±¸ºÐµË´Ï´Ù. 2024³â¿¡´Â ¼ÒÈ­±â Áúȯ ºÐ¾ß°¡ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹è°æ¿¡´Â Àå³» ¼¼±ÕÃѰú °ú¹Î¼º ´ëÀåÁõÈıº(IBS), ¿°Áõ¼º ÀåÁúȯ(IBD), ±Ë¾ç¼º ´ëÀå¿°, Å©·Ðº´ µîÀÇ Áúȯ°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸¸¼ºÁúȯÀº Àü ¼¼°èÀûÀ¸·Î À¯º´·üÀÌ ³ô°í Àå±âÀûÀÎ °ü¸®°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Àå³» ¼¼±ÕÃÑÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ´ëü¿ä¹ý ¹× º¸Á¶¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

¼ÒÈ­±â ÁúȯÀÇ ¹ßº´°ú ÁøÇà¿¡ ÀÖ¾î ¹Ì»ý¹° ºÒ±ÕÇüÀÇ ¿ªÇÒÀ» µÞ¹ÞħÇÏ´Â ¿¬±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. IBD¿Í IBS¸¦ Ÿ°ÙÀ¸·Î ÇÑ ¿©·¯ ÀÓ»ó ´Ü°èÀÇ Á¦Ç°ÀÌ °³¹ß ÁßÀ̸ç, °úÇÐÀû °ü½É°ú ÃæÁ·µÇÁö ¾ÊÀº ȯÀÚ ´ÏÁ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ½º, ½Å¹ÙÀÌ¿Àƽ½º µî ¼ÒÈ­±â °Ç°­À» À§ÇÑ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦°¡ Ãâ½ÃµÇ¸é¼­ ¼ÒºñÀÚÀÇ Á¢±Ù¼ºÀÌ ´õ¿í È®´ëµÇ¾î ÀÌ ºÐ¾ßÀÇ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

2024³â ºÏ¹Ì´Â Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹è°æ¿¡´Â ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ °­·ÂÇÑ Á¸Àç°¨, ¼±ÁøÈ­µÈ ÇコÄɾî ÀÎÇÁ¶ó, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª, ƯÈ÷ ¹Ì±¹¿¡¼­´Â ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È °úÇп¡ ÃÊÁ¡À» ¸ÂÃá ¼ö¸¹Àº ÀÓ»ó½ÃÇè°ú Çмú °øµ¿ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ FDA°¡ VOWST¿Í Rebyota¿Í °°Àº ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Ä¡·áÁ¦¸¦ ÃÖÃÊ·Î ½ÂÀÎÇÏ¿© Áß¿äÇÑ ±ÔÁ¦ ¼±·Ê°¡ µÇ´Â µî ±ÔÁ¦Àû Áö¿øµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÏ¹Ì¿¡¼­´Â Àå °Ç°­°ú ¿¹¹æÀû À£ºù¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È º¸ÃæÁ¦, ƯÈ÷ ÇÁ·Î¹ÙÀÌ¿Àƽ½º¿Í ½Å¹ÙÀÌ¿Àƽ½º¿¡ ´ëÇÑ ¼ÒºñÀÚ ±â¹ÝÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ³ôÀº ÀÇ·áºñ ÁöÃâ, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ ºÏ¹Ì´Â ¼¼°è Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå¿¡¼­ ¼±µµÀûÀÎ ÀÔÁö¸¦ ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç°º°, À¯Çüº°, Áúȯº°, Åõ¿© °æ·Îº°, ¼­ºñ½ºº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå(Á¦Ç°º°)

Á¦7Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÀǾàǰ¡¤º¸ÃæÁ¦ ½ÃÀå(À¯Çüº°)

Á¦8Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå(Áúȯº°)

Á¦9Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ÀǾàǰ¡¤º¸ÃæÁ¦ ½ÃÀå(Åõ¿© °æ·Îº°)

Á¦10Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Á¦Á¶ ½ÃÀå(¼­ºñ½ºº°)

Á¦11Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦12Àå Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå(Áö¿ªº°)

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Human Microbiome market is expected to reach USD 7.09 billion in 2031 from USD 1.40 billion in 2024, at a CAGR of 31.0% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2024
Forecast Period2025-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Disease, Drugs & Supplements Type, Drugs & Supplements Route of Administration, End User, Manufacturing Services, and Region
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the human microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

The probiotics segment accounted for the largest share of the human microbiome supplements segment in 2024.

Human Microbiome Market - IMG1

The market is segmented into human microbiome drugs, human microbiome supplements, and human microbiome diagnostics. The human microbiome supplements are analyzed across three key products: probiotics, prebiotics, and synbiotics. The segment with the biggest share in the human microbiome market in 2024 is probiotics. This dominance is attributed to their widespread use, strong consumer awareness, and established presence in over-the-counter health and wellness products. Probiotics are commonly used to support digestive health, boost immunity, and maintain gut microbial balance, making them a routine part of preventive healthcare. They are available in various formats, including capsules, powders, beverages, and functional foods, enhancing accessibility and consumer adoption. Additionally, a large body of clinical research supports the efficacy of specific probiotic strains, reinforcing trust among consumers and healthcare providers. The ability to pair probiotics with other bioactives like prebiotics or vitamins has further expanded their appeal across various demographics. Collectively, these factors have made probiotics the leading product type in the human microbiome supplements segment.

In 2024, the gastrointestinal diseases segment accounted for the largest share of the market.

The human microbiome market is segmented into gastrointestinal diseases, infectious diseases, endocrine & metabolic disorders, and other diseases. In 2024, the gastrointestinal diseases segment accounted for the largest share of the market. This is driven by the strong association between gut microbiota and conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, and Crohn's disease. These chronic disorders have a high global prevalence and often require long-term management, creating demand for alternative and adjunctive therapies that target the gut microbiome.

A growing body of research supports the role of microbial imbalances in the development and progression of gastrointestinal conditions, prompting increased investment in microbiome-based diagnostics and treatments. Several clinical-stage products targeting IBD and IBS are in development, reflecting scientific interest and unmet patient needs. The availability of microbiome supplements aimed at digestive health, such as probiotics and synbiotics, has further expanded consumer access and contributed to market growth in this segment.

In 2024, North America accounted for the largest share of the human microbiome market.

North America accounted for the largest share of the human microbiome market in 2024. This is due to several factors, including a strong presence of key market players, advanced healthcare infrastructure, and high levels of investment in microbiome research and development. The region hosts numerous clinical trials and academic collaborations focused on microbiome science, particularly in the United States. Regulatory support has also contributed to market growth, with the US FDA approving the first microbiome-based therapeutics, such as VOWST and Rebyota, setting important regulatory precedents. In addition, North America has a large and growing consumer base for microbiome supplements, particularly probiotics and synbiotics, driven by rising awareness of gut health and preventive wellness. High healthcare spending, increasing prevalence of chronic diseases, and favorable reimbursement policies further reinforce the leading position of North America in the global human microbiome market.

The primary interviews conducted for this report can be categorized as follows:

Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) are some of the key companies offering human microbiome drugs & supplements.

Research Coverage

This research report categorizes the Human Microbiome market by Product (Human Microbiome Drugs, Human Microbiome Supplements [Probiotics, Prebiotics, Synbiotics], Human Microbiome Diagnostics), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Drugs & Supplements Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Bacteria Products, and Others), Drugs & Supplements Route of Administration (Oral, Rectal), End User (Hospitals & Clinics, Long-term care Facilities, Other End Users), Manufacturing Service (Strain Development & Optimization, Fermentation & Downstream Processing, Formulation & Fill/Finish, Other Services) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the human microbiome market ecosystem is covered in this report.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the human microbiome market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the human microbiome market. This report covers the competitive analysis of upcoming startups in the human microbiome market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Startups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.

Competitive Assessment: Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 HUMAN MICROBIOME MARKET, BY PRODUCT

7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE

8 HUMAN MICROBIOME MARKET, BY DISEASE

9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION

10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE

11 HUMAN MICROBIOME MARKET, BY END USER

12 HUMAN MICROBIOME MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â